One-time treatment with Kebilidi (eladocagene exuparvovec-tneq) helped children with aromatic L-amino acid decarboxylase (AADC) deficiency gain new motor abilities within about a year, according to data from an ongoing clinical trial. The findings come from a Phase 2 clinical trial (NCT04903288) testing Kebilidi in 13 children with…